Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 163

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS–FTD

Open access
Irwin, Katherine E., Jasin, Pei, Braunstein, Kerstin E., Sinha, Irika R., Garret, Mark A., Bowden, Kyra D., Chang, Koping, Troncoso, Juan C., Moghekar, Abhay, Oh, Esther S., Raitcheva, Denitza, Bartlett, Dan, Miller, Timothy, Berry, James D., Traynor, Bryan J., Ling, Jonathan P., Wong, Philip C. · 2024 · Nature Medicine

Abstract

Although loss of TAR DNA-binding protein 43 kDa (TDP-43) splicing repression is well documented in postmortem tissues of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), whether this abnormality occurs during early-stage disease remains unresolved. Cryptic exon inclusion reflects loss of function of TDP-43, and thus detection of proteins containing cryptic exon-encoded neoepitopes in cerebrospinal fluid (CSF) or blood could reveal the earliest stages of TDP-43 dysregulation in patients. Here we use a newly characterized monoclonal antibody specific to a TDP-43-dependent cryptic epitope (encoded by the cryptic exon found in HDGFL2) to show that loss of TDP-43 splicing repression occurs in ALS–FTD, including in presymptomatic C9orf72 mutation carriers. Cryptic hepatoma-derived growth factor-like protein 2 (HDGFL2) accumulates in CSF at significantly higher levels in familial ALS–FTD and sporadic ALS compared with controls and is elevated earlier than neurofilament light and phosphorylated neurofilament heavy chain protein levels in familial disease. Cryptic HDGFL2 can also be detected in blood of individuals with ALS–FTD, including in presymptomatic C9orf72 mutation carriers, and accumulates at levels highly correlated with those in CSF. Our findings indicate that loss of TDP-43 cryptic splicing repression occurs early in disease progression, even presymptomatically, and that detection of the HDGFL2 cryptic neoepitope serves as a potential diagnostic biomarker for ALS, which should facilitate patient recruitment and measurement of target engagement in clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02788-5

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 42

  1. Barmada, S. J. et al. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J. Neurosci. 30, 639–649 (2010). · DOI · Paper page
  2. Brettschneider, J. et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann. Neurol. 74, 20–38 (2013). · DOI · Paper page
  3. Taylor, J. P., Brown, R. H. & Cleveland, D. W. Decoding ALS: from genes to mechanism. Nature 539, 197–206 (2016). · DOI · Paper page
  4. Zhang, Y. J. et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc. Natl Acad. Sci. USA 106, 7607–7612 (2009). · DOI · Paper page
  5. Ling, J. P., Pletnikova, O., Troncoso, J. C. & Wong, P. C. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science 349, 650–655 (2015). · DOI · Paper page
  6. Tan, Q. et al. Extensive cryptic splicing upon loss of RBM17 and TDP43 in neurodegeneration models. Hum. Mol. Genet. 25, 5083–5093 (2016).
  7. Brown, A. L. et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature 603, 131–137 (2022). · DOI · Paper page
  8. Estades Ayuso, V. et al. TDP-43-regulated cryptic RNAs accumulate in Alzheimer’s disease brains. Mol. Neurodegener. 18, 57 (2023). · DOI
  9. Sun, M. et al. Cryptic exon incorporation occurs in Alzheimer’s brain lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43. Acta Neuropathol. 133, 923–931 (2017). · DOI
  10. Jeong, Y. H. et al. Tdp-43 cryptic exons are highly variable between cell types. Mol. Neurodegener. 12, 13 (2017). · DOI
  11. Offit, M. B., Wu, T., Floeter, M. K. & Lehky, T. J. Electrical impedance myography (EIM) in a natural history study of C9ORF72 mutation carriers. Amyotroph. Lateral Scler. Frontotemporal Degener. 21, 445–451 (2020). · DOI
  12. Benatar, M., Wuu, J., Andersen, P. M., Lombardi, V. & Malaspina, A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann. Neurol. 84, 130–139 (2018). · DOI · Paper page
  13. Benatar, M. et al. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph. Lateral Scler. Frontotemporal Degener. 20, 538–548 (2019). · DOI
  14. Baughn, M. W. et al. Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies. Science 379, 1140–1149 (2023). · DOI · Paper page
  15. Lopez-Erauskin, J. et al. Stathmin-2 loss leads to neurofilament-dependent axonal collapse driving motor and sensory denervation. Nat. Neurosci. https://doi.org/10.1101/2022.12.11.519794 (2022). · doi:10.1101/2022.12.11.519794
  16. San Juan, I. G. et al. Loss of mouse Stmn2 function causes motor neuropathy. Neuron 110, 1671–1688 (2022). · DOI
  17. Vatsavayai, S. C. et al. Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. Brain 139, 3202–3216 (2016). · DOI · Paper page
  18. Seddighi, S. et al. Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD. Preprint at bioRxiv https://doi.org/10.1101/2023.01.23.525149 (2023). · doi:10.1101/2023.01.23.525149
  19. Lu, C. H. et al. Neurofilament light chain. Neurology 84, 2247–2257 (2015). · DOI · Paper page
  20. Thompson, A. G. et al. Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. Brain Commun. 4, fcac029 (2022). · DOI
  21. Benatar, M. et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 95, e59–e69 (2020). · DOI · Paper page
  22. Balendra, R., Moens, T. G. & Isaacs, A. M. Specific biomarkers for C9orf72 FTD/ALS could expedite the journey towards effective therapies. EMBO Mol. Med. 9, 853–855 (2017). · DOI
  23. Krishnan, G. et al. Poly(GR) and poly(GA) in cerebrospinal fluid as potential biomarkers for C9ORF72-ALS/FTD. Nat. Commun. 13, 2799 (2022). · DOI
  24. Traynor, B. J. et al. Amyotrophic lateral sclerosis mimic syndromes: a population-based study. Arch. Neurol. 57, 109–113 (2000). · DOI · Paper page
  25. Donde, A. et al. Splicing repression is a major function of TDP-43 in motor neurons. Acta Neuropathol. 138, 813–826 (2019). · DOI
  26. Mitsumoto, H., Brooks, B. R. & Silani, V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 13, 1127–1138 (2014). · DOI · Paper page
  27. Boer et al. TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J. Neurol. Neurosurg. Psychiatry 92, 86–95 (2021). · DOI · Paper page
  28. Chang, K. et al. Loss of TDP-43 splicing repression occurs early in the aging population and is associated with Alzheimer’s disease neuropathologic changes and cognitive decline. Acta Neuropathol. 147, 4 (2024). · DOI
  29. Feng, W. et al. NULISA: a novel proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing. Preprint at bioRxiv https://doi.org/10.1101/2023.04.09.536130 (2023). · doi:10.1101/2023.04.09.536130
  30. Josephs, K. A. et al. TDP-43 is a key player in the clinical features associated with Alzheimer’s disease. Acta Neuropathol. 127, 811–824 (2014). · DOI · Paper page
  31. Meneses, A. et al. TDP-43 pathology in Alzheimer’s Disease. Mol. Neurodegener. 16, 84 (2021). · DOI · Paper page
  32. Nelson, P. T. et al. Frequency of LATE neuropathologic change across the spectrum of Alzheimer’s disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. Acta Neuropathol. 144, 27–44 (2022). · DOI · Paper page
  33. Nelson, P. T. et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain J. Neurol. 142, 1503–1527 (2019). · DOI · Paper page
  34. Masaki, K. et al. RNA-binding protein altered expression and mislocalization in MS. Neurol. Neuroimmunol. Neuroinflamm. 7, e704 (2020). · DOI
  35. Kent, W. J. et al. The Human Genome Browser at UCSC. Genome Res. 12, 996–1006 (2002). · DOI · Paper page
  36. Nassar, L. R. et al. The UCSC Genome Browser database: 2023 update. Nucleic Acids Res. 51, D1188–D1195 (2022). · DOI · Paper page
  37. Rosenbloom, K. R. et al. ENCODE Data in the UCSC Genome Browser: Year 5 update. Nucleic Acids Res. 41, D56–D63 (2013). · DOI · Paper page
  38. Raney, B. J. et al. Track data hubs enable visualization of user-defined genome-wide annotations on the UCSC Genome Browser. Bioinformatics 30, 1003–1005 (2014). · DOI · Paper page
  39. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature https://doi.org/10.1038/35057062 (2001). · DOI · Paper page
  40. Frankish, A. et al. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res. 47, D766–D773 (2019). · DOI · Paper page
  41. Venkataraman, A. et al. A toolbox of immunoprecipitation-grade monoclonal antibodies to human transcription factors. Nat. Methods 15, 330–338 (2018). · DOI
  42. Armbruster, D. A. & Pry, T. Limit of blank, limit of detection and limit of quantitation. Clin. Biochem. Rev. 29, S49–S52 (2008).

Cited by

See all 163

Metadata

Authors
Irwin, K. E., Jasin, P., Braunstein, K. E., Sinha, I. R., Garret, M. A., Bowden, K. D., Chang, K., Troncoso, J. C., Moghekar, A., Oh, E. S., Raitcheva, D., Bartlett, D., Miller, T., Berry, J. D., Traynor, B. J., Ling, J. P., & Wong, P. C.
Venue
Nature Medicine
Published
2024-01-26
Volume
30
Issue
2
Pages
382-393
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4391258663
Cited by
163
References
17
FWCI
36.62
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • Johns Hopkins | SOM, JHU | Robert Packard Center for ALS Research, Johns Hopkins University
  • Target ALS
  • Amyotrophic Lateral Sclerosis Association
  • U.S. Department of Health & Human Services | National Institutes of Health (R01NS095969)
  • U.S. Department of Health & Human Services | NIH | National Institute on Aging (1ZIAAG000933)
  • Alzheimer’s Association

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS–FTD. https://app.cochat.ai/papers/10.1038/s41591-023-02788-5
The paper
Irwin, K. E., Jasin, P., Braunstein, K. E., Sinha, I. R., Garret, M. A., Bowden, K. D., Chang, K., Troncoso, J. C., Moghekar, A., Oh, E. S., Raitcheva, D., Bartlett, D., Miller, T., Berry, J. D., Traynor, B. J., Ling, J. P., & Wong, P. C. (2024). A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS–FTD. Nature Medicine. https://doi.org/10.1038/s41591-023-02788-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.